Department Of Justice

DOJ closes Brilinta investigation

By

AstraZeneca announced the end of the investigation Tuesday.

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

By

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

DOJ may cost Aegerion patients

The drugmaker's annual report indicates the company is concerned that an investigation into its marketing could dissuade doctors from prescribing Juxtapid.

Business briefs: Gilead, Shire, The Medicines Co., HHS

HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.

GSK in biggest-ever $3b marketing fraud settlement

GSK in biggest-ever $3b marketing fraud settlement

By

GlaxoSmithKline will pay $3 billion to settle state and federal charges that it promoted antidepressants Paxil and Wellbutrin for unindicated uses and withheld safety data on diabetes drug Avandia.

DOJ hit pharmas for $2.2 billion in 2011 False Claims Act cases

DOJ hit pharmas for $2.2 billion in 2011 False Claims Act cases

By

Pharmas shelled out $2.2 billion in False Claims Act fines and settlements with the Justice Department this year as the feds' healthcare fraud haul hit an all-time high.

Former sales rep to argue First Amendment protection in court

By

A federal appeals court has agreed to hear oral arguments about whether the First Amendment protects a sales rep's ability to share information about off-label uses of a drug.

CIAs pressure pharma to rethink sales rep compensation

By

Novartis's recent off-label settlement with the Department of Justice -- to the tune of $422 million -- also included the signing of a Corporate Integrity Agreement (CIA) requiring the Swiss-based manufacturer to review incentive-based compensation for reps, and to examine "the extent to which compensation is based on product performance," according to the CIA.

Forest Labs to pay $313 million in DOJ settlement

By

Forest Laboratories is the latest pharmaceutical company to settle unlawful marketing allegations with a multi-million dollar payout - over $313 million - to the Department of Justice (DOJ), just two weeks after Allergan agreed to pony up $600 million to settle illegal Botox marketing practices.

Allergan drops FDA lawsuit as part of off-label settlement

By

Before Allergan could begin settlement negotiations with the Department of Justice (DOJ) -- which ended with an agreement to pay $600 million on Wednesday -- DOJ required the Botox manufacturer to first withdraw a First Amendment lawsuit against the FDA filed last October.

Sales reps at J&J unit to get 'ride-alongs' as part of CIA

By

As part of an $81 million off-label settlement with the Department of Justice (DOJ), Ortho-McNeil Janssen Pharmaceuticals Inc. (OMJPI) sales reps will be buddied up with internal compliance monitors tasked with observing and reporting the rep's behavior out in the field.

Pfizer pays $2.3 billion for deceptive marketing practices

By

The world's largest pharmaceutical company, Pfizer, and its subsidiary Pharmacia & Upjohn Company Inc. have agreed to pay $2.3 billion, the largest healthcare fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability charges arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.